Patents by Inventor Robert F. Kaiko

Robert F. Kaiko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20020058673
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an opioid agonist, acetaminophen and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Application
    Filed: November 5, 2001
    Publication date: May 16, 2002
    Inventors: Robert F. Kaiko, Robert D. Colucci
  • Patent number: 6375957
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an opioid agonist, acetaminophen and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Grant
    Filed: February 11, 2000
    Date of Patent: April 23, 2002
    Assignee: Euro-Celtique, S.A.
    Inventors: Robert F. Kaiko, Robert D. Colucci
  • Patent number: 6344212
    Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphinein accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.
    Type: Grant
    Filed: January 8, 2001
    Date of Patent: February 5, 2002
    Assignee: Euro-Celtique S.A.
    Inventors: Robert F. Reder, Robert F. Kaiko, Paul D. Goldenheim
  • Publication number: 20020013301
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Application
    Filed: March 22, 2001
    Publication date: January 31, 2002
    Inventors: Robert F. Kaiko, Robert D. Colucci
  • Publication number: 20020004509
    Abstract: The invention relates in part to a method of reducing the abuse potential of an oral dosage form of an opioid analgesic, wherein an analgesically effective amount of an orally active opioid agonist is combined with an opioid antagonist into an oral dosage form which would require at least a two-step extraction process to be separated from the opioid agonist, the amount of opioid antagonist including being sufficient to counteract opioid effects if extracted together with the opioid agonist and administered parenterally.
    Type: Application
    Filed: March 22, 2001
    Publication date: January 10, 2002
    Inventors: Philip J. Palermo, Robert F. Kaiko, Robert D. Colucci
  • Patent number: 6277384
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Grant
    Filed: December 22, 1998
    Date of Patent: August 21, 2001
    Assignee: Euro-Celtique S.A.
    Inventors: Robert F. Kaiko, Robert D. Colucci
  • Publication number: 20010002259
    Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.
    Type: Application
    Filed: January 8, 2001
    Publication date: May 31, 2001
    Inventors: Robert F. Reder, Robert F. Kaiko, Paul D. Goldenheim
  • Patent number: 6231886
    Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an addition two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.
    Type: Grant
    Filed: May 14, 1999
    Date of Patent: May 15, 2001
    Inventors: Robert F. Reder, Paul D. Goldenheim, Robert F. Kaiko
  • Patent number: 6228863
    Abstract: The invention relates in part to a method of reducing the abuse potential of an oral dosage form of an opioid analgesic, wherein an analgesically effective amount of an orally active opioid agonist is combined with an opioid antagonist into an oral dosage form which would require at least a two-step extraction process to be separated from the opioid agonist, the amount of opioid antagonist including being sufficient to counteract opioid effects if extracted together with the opioid agonist and administered parenterally.
    Type: Grant
    Filed: December 22, 1998
    Date of Patent: May 8, 2001
    Assignee: Euro-Celtique S.A.
    Inventors: Philip J. Palermo, Robert D. Colucci, Robert F. Kaiko
  • Patent number: 5968547
    Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.
    Type: Grant
    Filed: September 29, 1997
    Date of Patent: October 19, 1999
    Assignee: Euro-Celtique, S.A.
    Inventors: Robert F. Reder, Paul D. Goldenheim, Robert F. Kaiko
  • Patent number: 5672360
    Abstract: Patients are treated with 24-hour oral sustained release opioid formulations which, upon administration, provide an initially rapid opioid absorption such that the minimum effective analgesic concentration of the opioid is more quickly achieved. These sustained release opioid formulations include an effective amount of at least one retardant material to cause said opioid analgesic to be released at a such a rate as to provide an analgesic effect after oral administration to a human patient for at least about 24 hours, and are characterized by providing an absorption half-life from 1 to about 8 hours. A method of titrating a human patient utilizing these sustained release opioid formulations is also disclosed.
    Type: Grant
    Filed: July 22, 1996
    Date of Patent: September 30, 1997
    Assignee: Purdue Pharma, L.P.
    Inventors: Richard S. Sackler, Robert F. Kaiko, Paul Goldenheim
  • Patent number: 5549912
    Abstract: A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated "q12h" (i.e., every 12 hour) administration through steady-state conditions.
    Type: Grant
    Filed: June 18, 1993
    Date of Patent: August 27, 1996
    Assignee: Euro-Celtique, S.A.
    Inventors: Benjamin Oshlack, Mark Chasin, John J. Minogue, Robert F. Kaiko
  • Patent number: 5508042
    Abstract: A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated "q12h" (i.e. every 12 hour) administration through steady-state conditions.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: April 16, 1996
    Assignee: Euro-Celtigue, S.A.
    Inventors: Benjamin Oshlack, Mark Chasin, John J. Minogue, Robert F. Kaiko